NCT05016869 2022-08-18
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
Clinical Trials
11 trialsNCT04247984 2022-03-11
A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Completed
NCT04695470 2021-01-07
Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer Patients
ChineseAMS
Phase 2 Unknown
NCT04380103 2020-05-08
A Phase I/II Study of XELOXIRI and Bevacizumab as First-line Treatment in Metastatic Colorectal Cancer
ChineseAMS
Phase 1/2 Unknown
NCT03927898 2019-04-25
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
ChineseAMS
Phase 2 Unknown
NCT02295774 2018-11-05
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
CosmoTech
Phase 2 Completed
NCT01694966 2017-11-06
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
CosmoTech
Phase 3 Completed
NCT02909114 2016-09-21
Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer
ChineseAMS
Phase 2 Unknown
NCT02688023 2016-02-23
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer
ChineseAMS
Phase 2 Unknown
NCT01529164 2013-11-27
Efficacy and Safety Study of Recombinant Endostatin Combined With Chemotherapy to Treat Advanced Colorectal Cancer
ChineseAMS
Phase 2 Unknown
NCT01679327 2012-09-06
Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
ChineseAMS
Phase 2 Unknown